Abstract
Clonal lymphoproliferative diseases of large granular lymphocytes (LGL) arise from both CD3-negative and CD3-positive cells, which define NK and T-LGL leukemia, respectively. Chronic neutropenia and anemia represent the most common clinical manifestation of these diseases but lymphocyte infiltration into bone marrow, spleen, and liver also occurs in some cases. The mechanism(s) responsible for expansion of the LGLs are unknown and the impact of lymphocytosis on the development of cytopenias is also incompletely defined. In this review, we discuss the incidence, clinical presentation, diagnostic criteria, and possible mechanisms of LGL leukemia pathogenesis. Despite the indolence of most cases of LGL leukemia, approximately 65% of patients will require therapy. There have been few controlled clinical trials conducted in this disease and long-term treatment is often required for sustained disease control. Novel therapies are primarily directed toward the targeted disruption of LGL leukemia survival. Conventional and novel therapeutics are discussed.
Keywords: LGL leukemia, large granular lymphocytes, NK-cell leukemia, T-cell leukemia, tipifarnib, alemtuzumab, siplizumab, immunosuppression
Current Cancer Therapy Reviews
Title: Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment
Volume: 3 Issue: 2
Author(s): Edna Ku, Todd Alekshun, Thomas P. Loughran, Lubomir Sokol and Pearlie K. Epling-Burnette
Affiliation:
Keywords: LGL leukemia, large granular lymphocytes, NK-cell leukemia, T-cell leukemia, tipifarnib, alemtuzumab, siplizumab, immunosuppression
Abstract: Clonal lymphoproliferative diseases of large granular lymphocytes (LGL) arise from both CD3-negative and CD3-positive cells, which define NK and T-LGL leukemia, respectively. Chronic neutropenia and anemia represent the most common clinical manifestation of these diseases but lymphocyte infiltration into bone marrow, spleen, and liver also occurs in some cases. The mechanism(s) responsible for expansion of the LGLs are unknown and the impact of lymphocytosis on the development of cytopenias is also incompletely defined. In this review, we discuss the incidence, clinical presentation, diagnostic criteria, and possible mechanisms of LGL leukemia pathogenesis. Despite the indolence of most cases of LGL leukemia, approximately 65% of patients will require therapy. There have been few controlled clinical trials conducted in this disease and long-term treatment is often required for sustained disease control. Novel therapies are primarily directed toward the targeted disruption of LGL leukemia survival. Conventional and novel therapeutics are discussed.
Export Options
About this article
Cite this article as:
Ku Edna, Alekshun Todd, Loughran P. Thomas, Sokol Lubomir and Epling-Burnette K. Pearlie, Large Granular Lymphocyte (LGL) Leukemia: Pathobiology, Diagnosis and Treatment, Current Cancer Therapy Reviews 2007; 3 (2) . https://dx.doi.org/10.2174/157339407780618452
DOI https://dx.doi.org/10.2174/157339407780618452 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Heat Shock Proteins: Therapeutic Perspectives in Inflammatory Disorders
Recent Patents on Inflammation & Allergy Drug Discovery The Role of Oxidative Stress in Anti-tumor Necrosis Factor Antibody Treatment in Crohn´s Disease
Current Medicinal Chemistry Protective Effects of Astaxanthin on Nephrotoxicity in Rats with Induced Renovascular Occlusion
Combinatorial Chemistry & High Throughput Screening Molecular Imaging of Vascular Inflammation
Current Pharmaceutical Design Fibroblast Growth Factor 2: From Laboratory Evidence to Clinical Application
Current Vascular Pharmacology In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Current Pharmaceutical Design HCV-Related Rheumatic Manifestations and Therapeutic Strategies
Current Drug Targets Nerve Growth Factor in Neurological and Non-Neurological Diseases: Basic Findings and Emerging Pharmacological Prospectives
Current Pharmaceutical Design Autoantibodies in Systemic Lupus: Quite a Lot or Just a Few?
Current Rheumatology Reviews The Neutrophil: An Underappreciated But Key Player in SLE Pathogenesis
Current Immunology Reviews (Discontinued) Novel Ideas of Gene Therapy for Atherosclerosis: Modulation of Cellular Signal Transduction of TGF-β Family
Current Pharmaceutical Design Vascular Effects of Estrogenic Menopausal Hormone Therapy
Reviews on Recent Clinical Trials Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review
Current Rheumatology Reviews Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology Modulation of Plasma Non Enzimatic Antioxidant Capacity (NEAC) by Plant Foods: the Role of Polyphenol
Current Topics in Medicinal Chemistry Vaccination and Induction of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Familial Mediterranean Fever
Current Rheumatology Reviews Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Review of Pediatric Uveitis
Current Pediatric Reviews A New Biomarker with High Outcome Prediction in IgA Nephropathy
Recent Patents on Biomarkers